Blog
Device Differences Matter: Why Addressing Negative Transfer Is Critical to Biosimilar Success
As biosimilar and interchangeable biologic therapies continue to expand patient access to treatment, the industry has an opportunity to focus on more than affordability and availability. The patient experience must remain a priority, particularly as new delivery devices enter the market.
Learn more